An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
ASLAN Pharmaceuticals announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease (COPD) has been accepted for presentation at the American Thoracic Society International Conference 2024. The poster will discuss how Eblasakimab alleviates bronchial airway constriction in COPD patients. The presentation will be made by Dr. Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals ha annunciato che un abstract riguardante eblasakimab nella Malattia Polmonare Ostruttiva Cronica (COPD) è stato accettato per una presentazione alla Conferenza Internazionale della Società Toracica Americana 2024. Il poster discuterà come l'Eblasakimab allevia la costrizione delle vie aeree bronchiali nei pazienti con COPD. La presentazione sarà tenuta dal Dr. Ferda Cevikbas, Capo della Scienza Traslazionale presso ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals anunció que un resumen sobre eblasakimab en la Enfermedad Pulmonar Obstructiva Crónica (EPOC) ha sido aceptado para su presentación en la Conferencia Internacional de la Sociedad Torácica Americana 2024. El póster discutirá cómo el Eblasakimab alivia la constricción de las vías respiratorias bronquiales en pacientes con EPOC. La presentación será realizada por el Dr. Ferda Cevikbas, Jefe de Ciencia Translacional en ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals는 만성 폐쇄성 폐질환(COPD)에서의 에블라키맙에 관한 초록이 2024년 미국 흉부학회 국제 회의에서 발표될 예정이라고 발표했습니다. 포스터는 에블라키맙이 COPD 환자의 기관지 공기도 수축을 완화하는 방법에 대해 논의할 것입니다. 발표는 ASLAN Pharmaceuticals의 전환 과학 책임자인 페르다 체비크바스 박사가 맡게 됩니다.
ASLAN Pharmaceuticals a annoncé qu'un résumé sur l'eblasakimab dans la Maladie Pulmonaire Obstructive Chronique (MPOC) a été accepté pour présentation à la Conférence Internationale de la Société Thoracique Américaine 2024. L'affiche discutera comment l'Eblasakimab soulage la constriction des voies aériennes bronchiques chez les patients atteints de MPOC. La présentation sera faite par le Dr. Ferda Cevikbas, responsable de la Science Translationnelle chez ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals gab bekannt, dass ein Abstract über Eblasakimab bei der Chronisch Obstruktiven Lungenerkrankung (COPD) für eine Präsentation auf der Internationalen Konferenz der Amerikanischen Thorax-Gesellschaft 2024 angenommen wurde. Das Poster wird erörtern, wie Eblasakimab die bronchiale Atemwegsverengung bei COPD-Patienten lindert. Die Präsentation wird von Dr. Ferda Cevikbas, Leiter der Translationalen Wissenschaft bei ASLAN Pharmaceuticals, durchgeführt.
Positive
None.
Negative
None.
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society International Conference 2024. The conference is taking place in San Diego, California, from May 17 to 22, 2024.
American Thoracic Society International Conference poster details
Poster title: Eblasakimab Significantly Alleviates IL-4 and IL-13 Induced Bronchial Airway Constriction in COPD-Derived Lung Slices (Poster ID 13753)
Presentation date and time: Monday, May 20, 2024, 9:15 am PDT
Presenter: Dr Ferda Cevikbas, Head, Translational Science, ASLAN Pharmaceuticals
The posters will be available to view online in the Publications section of ASLAN’s website following presentation.
About eblasakimab
Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, a key pathway driving several allergic inflammatory diseases. Eblasakimab’s unique mechanism of action enables specific blockade of the Type 2 receptor and has the potential to improve upon current biologics used to treat allergic disease. By blocking the Type 2 receptor, eblasakimab prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13) – the key drivers of inflammation in AD and Type 2-driven COPD. ASLAN announced positive results from the Phase 2b TREK-AD study of eblasakimab in moderate-to-severe biologic-naïve AD patients in July 2023, and is currently investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the Phase 2 trial, TREK-DX.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is currently investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the TREK-DX Phase 2 trial, with topline data expected at the end of 2024. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in Q3 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the ASLAN website or follow ASLAN on LinkedIn.
What is the title of the poster presentation at the American Thoracic Society International Conference 2024?
The title of the poster presentation is 'Eblasakimab Significantly Alleviates IL-4 and IL-13 Induced Bronchial Airway Constriction in COPD-Derived Lung Slices' with Poster ID 13753.
When is the presentation scheduled to take place?
The presentation is scheduled for Monday, May 20, 2024, at 9:15 am PDT.
Who will be presenting at the conference?
Dr. Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals, will be presenting at the conference.
Where can the posters be viewed online?
The posters will be available to view online in the Publications section of ASLAN’s website following the presentation.
ASLAN Pharmaceuticals Limited American Depositary Shares
aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.
